Clinical trial · Observational
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
TRIMPACT: A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line (Stage IV) Treatment in Patients With Non-Small Cell Lung Cancer With PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atezolizumab | — | UNRESOLVED | — |
| NSCLC Stage IV | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| PD-L1 Gene Mutation | — | UNRESOLVED | — |
| Real World Study | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Atezolizumab Real-World Cohort
- description
- This observational cohort consists of patients with stage IV non-small cell lung cancer (NSCLC) who receive first-line atezolizumab in routine clinical practice. Participants are included based on real-world treatment decisions made by their physicians, and no study-mandated interventions or procedures are required. The cohort reflects patients treated according to local standards of care, allowing evaluation of real-life treatment patterns, clinical outcomes, and safety in this population.
Primary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- Up to 24 months
- description
- Overall survival (OS) is defined as the time from the initiation of atezolizumab treatment to the date of death from any cause.
Secondary outcomes (7)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- Up to 24 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent form. * Diagnosis of stage IV non-small cell lung cancer. * Male or female patients aged 18 years or older. * Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye. * Patients who have received up to 3 cycles of atezolizumab at the screening visit. Exclusion Criteria: * Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication. * Known or suspected hypersensitivity to atezolizumab. * Pregnant or breastfeeding women.
References
Publications (0)
Data not yet available